Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNB4 | P30926 | 4/20 | 0.48 |
| ▸ | CHRNA3 | P32297 | 4/20 | 0.48 |
| ▸ | ACHE | P22303 | 3/20 | 0.39 |
| ▸ | GRIA1 | P42261 | 1/20 | 0.39 |
| ▸ | SIRT2 | Q8IXJ6 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | NPC1 | O15118 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.38 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.37 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.37 |
| ▸ | PTPRC | P08575 | 1/20 | 0.37 |
| ▸ | S100A4 | P26447 | 1/20 | 0.37 |
| ▸ | CASP1 | P29466 | 1/20 | 0.36 |
| ▸ | CASP3 | P42574 | 1/20 | 0.36 |
| ▸ | CASP4 | P49662 | 1/20 | 0.36 |
| ▸ | CASP7 | P55210 | 1/20 | 0.36 |
| ▸ | CASP9 | P55211 | 1/20 | 0.36 |
| ▸ | CASP6 | P55212 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4491493 | 1.00 | CHRNB4 (0.48) | CHRNB4CHRNA3ACHEGRIA1SIRT2 | |
| SCHEMBL7237974 | 0.81 | SIRT2 (0.44) | CHRNB4CHRNA3ACHESIRT2MEN1 | |
| SCHEMBL2062819 | 0.81 | CHRNB4 (0.41) | CHRNB4CHRNA3ACHESIRT2ALDH1A1 | |
| SCHEMBL2791701 | 0.81 | CHRNB4 (0.51) | CHRNB4CHRNA3SIRT2ALDH1A1AR | |
| SCHEMBL13681596 | 0.81 | CHRNB4 (0.51) | CHRNB4CHRNA3SIRT2ALDH1A1AR | |
| SCHEMBL5122957 | 0.81 | CHRNB4 (0.51) | CHRNB4CHRNA3SIRT2ALDH1A1AR | |
| SCHEMBL31562963 | 0.80 | GRIA1 (0.55) | CHRNB4CHRNA3ACHEGRIA1MEN1 | |
| SCHEMBL4498044 | 0.80 | ALPL (0.46) | GRIA1AR | |
| SCHEMBL5986573 | 0.80 | CYP19A1 (0.45) | GRIA1MEN1KMT2AAR | |
| SCHEMBL4492290 | 0.80 | CHRNB4 (0.42) | CHRNB4CHRNA3GRIA1MEN1NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7504390-B2 | Benzoxazepine derivatives and their use as AMPA receptor stimulators | N.V. ORGANON (NL) | 2009-03-17 | — | — | US | disclosed |
| US-20080139529-A1 | BENZOXAPZEPINE DERIVATIVES AND THEIR USE AS AMPA RECEPTOR STIMULATORS | N.V. ORGANON (NL) | 2008-06-12 | — | — | US | disclosed |
| EP-1399450-B1 | BENZOXAZEPINE DERIVATIVES AND THEIR USE AS AMPA RECEPTOR STIMULATORS | ORGANON NV (NL) | 2008-03-19 | — | — | EP | disclosed |
| US-7307073-B2 | Benzoxazepines derivatives and their use as AMPA receptor stimulators | N.V. ORGANON (NL) | 2007-12-11 | — | — | US | disclosed |
| US-20040171605-A1 | Benzoxazepines derivatives and their use as ampa receptor stimulators | MERCK SHARP & DOHME B.V. (NL) | 2004-09-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040171605-A1 | Benzoxazepines derivatives and their use as ampa receptor stimulators | CHRNA4, CHRNA10, CHRNA9 | CHRNB4 43/4885CHRNA3 21/4885ACHE 1392/4885 |
| US-20080139529-A1 | BENZOXAPZEPINE DERIVATIVES AND THEIR USE AS AMPA RECEPTOR STIMULATORS | GRIN1, GRIA4, CHRNA4 | CHRNB4 50/4885CHRNA3 34/4885ACHE 1529/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.